Table_3:一种新型m6A相关基因签名可影响肺腺癌免疫状态并预测预后和药物敏感性

肺腺癌m6A相关基因预后签名研究的表格数据,涉及TCGA数据、预后模型、免疫状态与药物敏感性分析。

NIAID Data Ecosystem
浏览 2
表格分类immune microenvironmentprognosislung adenocarcinomam6A related genesnomogram
Table_3_A Novel M6A-Related Genes Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma.xls

基本信息

模态
表格
大小
0.000007428 GB
任务类型
分类
许可
CC BY 4.0
创建/更新时间
2026-10-10
版本
v1

资源简介

Table_3:一种新型m6A相关基因签名可影响肺腺癌免疫状态并预测预后和药物敏感性

【一句话概览】

本数据集是 figshare 公开的结构化表格数据集,收录 1 个文件、合计 7.43 KB,主题涵盖 immune microenvironment、prognosis、lung adenocarcinoma、m6A related genes、nomogram,可用于统计建模、特征工程与队列分析,CC BY 4.0 许可开放获取。

【数据集背景】

本数据集源站标题为《Table_3_A Novel M6A-Related Genes Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma.xls》。源站首次发布:2022-07-04。

【数据内容】

源站原始描述:Lung adenocarcinoma (LUAD) is a primary cause of cancer-related death around the world and has a poor outcome and high incidence. Treatment options are, however, restricted. One of the most critical factors in cancer and metastasis is the N6-methyladenine (m6A) alteration on RNA. This modification could alter gene expression and even function at numerous levels, such as the stability, translocation and translation of RNA splicing. This study aimed to construct an m6A-related genes signature to a…

主表 Table_3_A Novel M6A-Related Genes Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma.xls 含 9 列、样本前 39 行结构完整。

【数据结构与技术规格】

文件数 1 个,合计 7.43 KB。Table_3_A Novel M6A-Related Genes Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma.xls:text/plain,7.43 KB。数据集 DOI:10.3389/fimmu.2022.923533.s004。

【主题与分类】

源站学科分类:Transplantation Immunology、Tumour Immunology、Immunology not elsewhere classified、Immunology、Veterinary Immunology、Animal Immunology。主题标签:immune microenvironment、prognosis、lung adenocarcinoma、m6A related genes、nomogram。

【适用方向】

结构化表格数据可直接用于统计建模、特征工程与队列分析。结构化表格数据可直接用于统计建模、特征工程与队列分析。

【获取与许可】

源站页面:https://frontiersin.figshare.com/articles/dataset/Table_3_A_Novel_M6A-Related_Genes_Signature_Can_Impact_the_Immune_Status_and_Predict_the_Prognosis_and_Drug_Sensitivity_of_Lung_Adenocarcinoma_xls/20220828

使用许可:CC BY 4.0(https://creativecommons.org/licenses/by/4.0/)。

规范引用:Wang, Xuewen; Zhao, Chengfei; Huang, Dandan; Liu, Zhoujie; Liu, Mengmeng; Lin, Fei; et al. (2022). Table_3_A Novel M6A-Related Genes Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma.xls. Frontiers. Dataset

【使用注意】

· 源站最后修改于 2023-06-17,引用时请注意版本时效。

官方服务

专家保障全链路合规授权与标注交付

陕川双基地 × 超十家三甲医院直连

从合规授权、采集治理、专业标注到数据集交付,我们提供全链路闭环服务,让高质量临床数据即拿即用。

⚡️ 需要原始数据或标注支持?联系我们获取定制方案。

帮我联系

下载信息

注册下载

需要注册 Kaggle 账号并登录后下载,适合需要跟踪下载记录和使用 API 的用户。

暂未开放

公开下载

无需注册即可直接获取公开样本或文档,适合快速预览和评估数据集质量。

免登录

有偿下载

公开数据集受托下载与技术交付服务。

提供高速下载与技术交付服务(收技术服务费,非数据销售)

暂未开放

当前数据集主要来源为 Kaggle 公开托管,完整影像包建议通过原始链接或 Kaggle API 获取。

使用方式

数据集获取(Figshare)

命令行下载

curl -L -o "Table_3_A Novel M6A-Related Genes Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma.xls" "https://ndownloader.figshare.com/files/36141789"

文件清单

  • Table_3_A Novel M6A-Related Genes Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma.xls(7.43 KB)

文件总体积 7.43 KB(源站 API 实测)。

数据加载示例(图像类)

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Lung adenocarcinoma (LUAD) is a primary cause of cancer-related death around the world and has a poor outcome and high incidence. Treatment options are, however, restricted. One of the most critical factors in cancer and metastasis is the N6-methyladenine (m6A) alteration on RNA. This modification could alter gene expression and even function at numerous levels, such as the stability, translocation and translation of RNA splicing. This study aimed to construct an m6A-related genes signature to accurately predict the prognosis of LUAD patients. From TCGA datasets, the LUAD patient data and m6A-related genes were retrieved. LUAD patients’ mutational features and differentially expressed genes (DEGs) were investigated. An univariate and LASSO model with m6A-related genes were constructed for the prediction of outcomes in LUAD. It was possible to develop a prognostic nomogram that could quantitatively predict LUAD patients’ overall survival chances at 1, 3, and 5 years. Research into biological processes and cell pathways was carried out using GSEA. This study found six m6A-related DEGs in LUAD patients, and three of these DEGs(HNRNPC, IGFBP3 and IGF2BP1) were linked to the clinical outcomes of LUAD patients. We found that the overall survival rate for all LUAD patients with high-risk subgroup was considerably lower. According to ROC curves, the prognostic signature demonstrated a high degree of accuracy in predicting future outcomes. In addition, we created a novel nomogram achieved great accuracy with this one as well. The researchers also found that the novel signature might favorably modulate the immune response, and high-risk scores samples were more susceptible to numerous chemotherapeutic medicines. Overall, we developed a m6A-related gene prognostic signature that effectively predicted outcomes of LUAD patients and gave an immunological perspective for creating customized therapeutics.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fimmu.2022.923533.s004(source: https://frontiersin.figshare.com/articles/dataset/Table_3_A_Novel_M6A-Related_Genes_Signature_Can_Impact_the_Immune_Status_and_Predict_the_Prognosis_and_Drug_Sensitivity_of_Lung_Adenocarcinoma_xls/20220828)。

数据缺失?

依托陕西、四川两大基地,我们与超过十家三甲医院建立直接合作关系,覆盖合规授权、采集治理、专业标注、数据交付的全流程,为AI医疗团队提供即拿即用的高质量临床数据。

⚡️ 需要数据支持或标注服务?立即联系我们获取专业方案。

获取专属数据定制方案